Introduction: Keloids are benign dermal tumors that generally form by local fibroblast proliferation and excessive collagen production following skin trauma. Several methods have been described for the treatment of keloid, often with suboptimal results and recurrences.
Introduction
K eloids are benign dermal tumors that generally form bylocal fi broblast prolifera on and excessive collagen produc on following skin trauma. 1 Rarely, it can occur spontaneously in the absence of antecedent trauma. 2 Keloids are unique to human andoccur more frequently in individuals with darker skin. 3 The propensity of keloid forma on in darker skin types is thought to be due in part by the larger mul nucleated fi broblasts that have been described in this popula on. 4 Keloids vary in size and shape, and do notregress spontaneously. They can be pedunculated or elevated with a fl at surface, and may grow to sizes that can be disfi guring or crippling. Keloids range in consistency from so and doughy torubbery hard and they may be tender, painful, pruri c, orcause a burning sensa on. 5 Histologically, they are characterized by exuberantdermal collagen forma on with random orienta on and assembly of the individual collagen fi bers. Uncontrolled fi broblast ac vity and excess collagen lead to overabundant extracellular matrix forma on, and are the hallmark o hese tumors. 6 Although the exact pathogenesis of keloid is not elucidated, it has been known that keloid fi broblasts, when compared with normal fi broblasts, have lower rates of apoptosis. 7 In addi on, these cells over produces type I collagen and expresses higher levels of cytokines and growth factors, which infl uences prolifera on and collagen synthesis by fi broblasts. Another factor studied in the pathogenesis of keloid forma on is the role of increased skin tension. This has postulated the skin injury-wound tension theory as the corner stone theory for keloid forma on. 1 A wide range of treatment modali es for keloid exists, which includes cryotherapy, surgical excision, intralesional injec on with pharmacologic agents, mechanical pressure, and silicone gel dressings. None of these are 100% successful. Moreover, studies have shown lowered self-esteem and impaired quality of life in aff ected individuals. 8 This calls for theinves ga on of new therapeu c interven ons. Recently, a en on has been drawn to the possible benefi cial eff ects of newer therapies like lasers, radiofrequency, photodynamic therapy, and UVA1 irradia on. In the present review, we aim to update literature that provides informa on regarding upcoming therapeu c modali es for the treatment of keloids.
Many diff erent lasers have been studied and u lized in the treatment of keloids including carbon dioxide (CO2) laser, 2940-nm erbium-doped: y rium, aluminum and garnet (Er:YAG) laser, 1064-nm neodymiumdoped:y rium, aluminum and garnet (Nd:YAG) laser, and 585-595 nm pulsed-dye lasers (PDL). CO2 and Er:YAG are abla ve lasers, while Nd:YAG and PDL are non abla ve lasers. CO2 laser and Er:YAG laser emit beams absorbed by water in skinresul ng in local ssue destruc on. 9, 10 Since the energy of the Er:YAG laser is due to its wavelength (2,940 nm) -largely absorbed by water, there is only very minor heat dissipa on into the surrounding ssue; hence the term "cold" ssue abla on. 11 The CO2 laser, on the other hand, with a wavelength of 10,600 nm, generates moreheat in the surrounding ssue and also coagulates small blood vessels. 11 Nd: YAG laser is hypothesized to primarily treat keloids by damaging deepdermal blood vessels.
12 Also, it may directly suppress fi broblastcollagen expression.
12 Due to its wavelength (1,064 nm), however, the depth of penetra on of theNd:YAG laser is much greater, a property shown to be useful in the treatment of Keloid scars. PDL is hypothesized to treat keloids by selec ve damage of blood vessels that supply the scar. 13 With a wavelength of 595nm or 585nm, oxyhemoglobin is the target chromophore of pulse dye laser (PDL). The near infrared diode laser has energy and wave length characteris cs that specifi cally target the so ssues. 14 The 980 nm diode laser is selec vely absorbed by haemoglobin and selec vely destroys blood vessels, minimising injury to the surrounding healthy skin.The light energy released by the diode laser transformsinto heat, resul ng in the vaporiza on of cells, a processreferred to as the photothermal eff ect. 14 Radiofrequency ssue volume reduc on (RFTVR) uses very low levels of radiofrequency energy tocreate controlled protein denatura on or necrosis insossue structures. 15 Radiofrequency abla oncan be considered as minimally invasive treatment modality with no major disadvantages. 16 Because of its mechanism of ac on, RFTVR appeared suitable for treatment of keloids.
Photodynamic therapy (PDT) is an established mode o reatment for skin condi ons such as Basel Cell Carcinoma, Ac nic Keratosis and Bowens Disease.
This therapy is a non-invasive therapy that u lizes light treatments along with an applica on of a photosensi zing agent (PA). The PA is applied to the skin, causing the skin to become more suscep ble, or recep ve, to light. 17 Once the incuba on period of PA is complete, light of a specifi c wave length is directed onto the area to be treated, ac va ng the protoporphyrin 9 (PpIX) and resul ng in the forma on ofcytotoxic reac ve oxygen species. This causes cell apoptosis or necrosis, membrane and mitochondrialdamage and ac vates many signalling molecules, e.g. TNF-, interleukins 1 and 6. 18 The poten al mechanism of PDT in keloid may involve modula on of the growth factor and cytokine expression. 18 Long-wave length UVA1 is diff erent from other UV phototherapies because it off ers deeper penetra on as well as targe ng fi brosis and other structures, i.e. fi broblasts, T-lymphocytes, Langerhans cells,mast cells, endothelial cells.
19 UVA1 (340-400nm) acts deeper in the dermis andeven in the subcutaneous ssue. Moreover, around 20% of the radia on reaches vascular system, which, according tosome authors, provides grounds for a poten al systemic ac on of this radia on range.
19 UVA1 irradia on has been reportedto be eff ec ve for the treatment of morphea and systemicsclerosis through the induc on of collagenase I [matrix metallo proteinase I (MMP-1)] produc on by fi broblasts and decreased synthesis of procollagen. The effi cacy of UVA1for the treatment of keloid scarring may be partly the result of this ac on.
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Method
A systema c review of the literature was performed for the original ar cles related to the treatment of keloids. The search terms 'keloids' and 'lasers' or 'radiofrequency' or 'PDT' or 'UVA1' was entered into a search of the Na onal Library of Medicine's PubMed Database. The search returned a total of 188 sources, of which, 26 ar cles met our inclusion criteria. Published clinical trials, case series, case reports, retrospec ve studies and le ers repor ng on keloid treatment using abla ve lasers, non-abla velasers, radiofrequency, PDT or UVA1 were included in this review. Unfortunately, randomized clinical trials on the relevant topic were not found. Only human studies and English language ar cles were selected. Ar cles about other skin condi onsor scar types other than keloids, including those that collec vely men oned hypertrophicscars and keloids, were excluded.In vitro studies were excluded. Figure 1 shows schema c diagram of search strategy lis ng the ar cles that met inclusion or exclusion criteria and Table 1 summarizes the characteris cs of the 26 studies included in this review.
Laser therapy
Apfelberg DB et al reported the earliest study on laser treatment for keloids in 1984. 21 Thirteen pa ents with well-established keloid scars of the trunk or earlobe were treated with either mul ple-bore-hole argon technique alone or in combina on with totalexcision with the C0 2 laser. Only one pa ent with an earlobe keloid treated with argon laser alone showed total disappearance of keloid, all other pa ents had no improvement. In 1989, Apfelberg DB et al again treated seven pa ents with keloid on the trunk, nuchal region, back, and earlobe. 22 Under local anesthesia, the keloids were excised sharplydown to the base by CO2 laser. Only one pa ent with earlobe keloid showed great improvement a er only nine months' follow-up, all other pa ents had recurrence.
Ang CC et al reported case records of 16 pa ents with earlobe keloids. 23 The pa ents received diff erent treatment modali es including CO2 laser abla on, or cold steel surgery, or combined surgery and CO2 laser abla on, or 40 mg/ml of intralesional triamcinolone acetonide. Both the CO2 laser abla on and cold steel surgery were equally useful in reducing the size of the earlobe keloids, but were not eff ec ve in preven ng regrowth of the keloids, even with adjunc ve intralesional steroids. In contrast to the above studies, Morosolli AR et al observed a very good esthe c and func onal result in a pa ent with anearlobe keloid treated with CO2 laser with a 0.8-mm focus, 7 W, a power density of 2.5 W/cm2, in a con nuous mode. 24 Similarly, Nicole G et al reported eff ec veand well-tolerated treatment of keloids by CO2 laser. 25 Fi y pa ents with moderate to severe keloids received regional treatments (deltoid, elbow, chin, and ear) with a high-energy pulsed CO2 laser. Diminished scarbulk with a reduc on in scar height and textural improvement was noted in all the pa ents. Scrimali L et al compared the eff ect of laser CO2 versus radiotherapy following surgical excision in the treatment of keloid and found that CO2 laser a er surgical excision of keloids has great results with no recurrence and without the risk of carcinogenesis. 26 Yang Q et al reported a study with successful use of combina on approach. 27 One hundred and fi y onesites of keloids in 122 pa ents weretreated with combina on methods of con nuous-wave CO2 laser, ultra-pulse CO2 laserand 32P radia on. One hundred elevenof 151 evaluated sites scored "excellence"and 40 belonged to "eff ec veness". These pa ents demonstrated local control and have remained free of local recurrence for more than two years. Studies on laser therapy for keloids have shown more exci ng results with PDL comparing to CO2 lasers. However, mul ple treatments (>six) were required to yield be er results than fewer treatments: 79% versus 50%, respec vely. Twelve months a er fi nal PDL treatments, keloid regression ( 50%) had occurred in 26 out of 30 pa ents. 28 Another study showed be er result with PDL only a er three sessions of treatment. 29 Using the Vancouver scar scale (VSS), there was an average decrease of 20.85 12.33% a er PDL treatment. Eke U et al reported on the successful use of surgical shave-excision followed by single-pass PDL therapy for the treatment of keloid. 30 Similarly, Cannarozzo G et al also reported a successful use of fl ash lamppumped PDL. 31 This study recruited 59 pa ents who received four to six treatment sessions with a fl ash lamppumped PDL. A total of 29 pa ents out of 59 achieved excellent clearance, 15pa ents achieved good to moderate clearance, and 12 pa ents obtained slight improvement. Only three subjects had li le or no removal of their lesion. Mar n MS et al combined frac onal CO2 laser with PDL as well as the injec on of triamcinolone acetonide into the keloids refractory to solitary treatments of triamcinolone acetonide injec on and other laser modali es. 32 Treatments were carried out once per month for seven sessions. A er fi ve sessions, drama c improvement in the lesions was seen.
Recently, studies on other types of lasers including Nd:YAG lasers, Er:YAG lasers, and 980nm diode laser with adjunc ve intralesional or topical cor costeroids have shown good results in trea ng keloids. 14,33,34, The success rate in these studies varied from 50% to 75%. 14, 34 More recently, Chen XE et al reported a successful use of long-pulsed Nd:YAG laser in combina on with intralesional injec on of diprospan and 0.5 ml 5-fl uorouracil. 35 In terms of invasiveness, two studies provided least invasive therapy. [34] [35] [36] Cavalie M et al treated 23 pa ents with 70 keloids with a 2940-nm abla ve frac onal erbium laser and topical betamethasone cream. 34 The median percentage of improvement was 50% and a recurrence was observed for eight lesions at 18 months follow up. Similarly, Park JH et al treated keloids with an abla ve frac onal erbium-YAG laser and an intralesional injec on or topical applica on of cor costeroid and concluded this treatment a promising modality for the treatment of keloids.
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Radiofrequency
Some small studies have proven the clinical safety and effi cacy of RF in the treatment of keloids, especially in combina on with adjuvant ILCS. It was in 2011, when Kai Fruth et al for the fi rst me applied RFTVR in 14 pa ents with keloids of the auricle. 15 In six pa ents, RFTVR was thesole treatment modality applied, and in seven pa ents IL steroid injec on was also performed. Good cosme c results were achieved in 10 of 14 pa ents. In 2013, Klockars T et al presented the second paper on this promising novel treatment op on. 37 They applied RF abla on in 11 pa ents (13 auricles) with single treatment session for all except one pa ent who was treated three mes with three and 13 months interval. The eff ect of RF abla on was excellen n six auricles, good in fi ve auricles and moderate in one auricle. In 2015, Weshay AH et alpresented the study on the combined eff ect of RF and IL steroids in the treatment of keloids. 38 It was a pilot study on 18 pa ents who were subjected to three to four sessions of RF followed by IL steroid injec on. A signifi cant reduc on of volume of all lesions in all pa ents was noted, with a mean volume reduc on of 95.4%.
Photodynamic therapy
In 2010, Nie Z et al reported the fi rst study on PDT of keloids. 18 It was a case report of the pa ent who had keloid under her chin for four years that had failed to respond to several other treatments,including surgical resec on, but showed substan alimprovement with PDT. A er fi ve sessions of MAL-PDT over a period of 5 months, the pa ent's lesion had considerably reduced in size and become fl a ened and there was no recurrence at 1-year follow-up. Ud-Din S et alalso, in their clinical trial of 20 pa ents,proved the effi cacy of PDT for keloids. 39 The pa entsunderwent three treatments of MAL-PDT at weekly intervals. All pa ents showed marked improvement except one pa ent who experienced recurrence of KD.All other pa ents had no recurrence at nine-month follow-up.
UVA1 irradiation
Asawanonda P et al reported the fi rst study on the successful use of UVA1 irradia on for the treatment of keloids in 1999. 40 It was a case report where pa ent received 2860 J/cm2 of UVA1 irradia on and responded well to the treatment. In contrary to this ar cle repor ng a successful treatment, HannukselaSvahn A et al found no eff ect of UVA1 irradia on on stable keloids. 41 This was a study performed on threepa ents with a several years history of a stable keloid secondary to tuberculinvaccine in the one pa ent and to acne in the other 2 pa ents. The pa ents received 1700, 1800 and 1500 J/cm2 of UVA1 irradia on given strictly to the lesion alone. Table 1 contd.
The treatment was tolerated well, and two of the pa ents experienced subjec vely so ening of the keloid but none had any macroscopic reduc on of the scar. The lack of response in the second experiment might be due to low dose of UVA1 comparing to the fi rst study where high dose of UVA1 (2860 J/cm2) was used. Recently in 2016, Polat M et al presented the results from two pa ents who underwent high dose UVA1 laser therapy. 42 The treatment protocol applied in this study was: 160 J/cm2 three mes a week for the fi rst two weeks then 180 J/cm2 for two weeks, 230 J/ cm2 for three weeks, and 250 J/cm2 for six weeks for one pa ent. 140 J/cm2 three mes a week for the fi rst three weeks, and then at 160 J/cm2 for three weeks, 180 J/cm2 for two weeks,230 J/cm2 for two weeks, and 250 J/cm2 for two weeks for another pa ent. An improved VSS score was observed following treatment and complaint of itching and tenderness decreased signifi cantly.
Discussion
In the past, the most recommended treatment strategy for keloid has been prophylaxis using silicone gel shee ng or paper tape star ng on the second week a er wounding, combined with other treatments, including massage, pressure therapy and intralesional cor cotherapy, depending on each pa ent and scar's origin and type. 43 None of these therapeu c op ons has been found completely eff ec ve and sa sfactory. Moreover, pa ents with keloid scars suff er a severe impairment of quality of life, by causing physical, psychological and social sequelae. 44 Recently, the promising results of some big and small studies has drawn a en on to the possible benefi cial eff ects of upcoming therapeu c modali es like lasers, radiofrequency, photodynamic therapy, and UVA1 irradia on. Among lasers, CO 2 laser was seen to be eff ec ve for keloids as a solo therapy. 24, 25 It was also eff ec ve as an adjuvant therapy following surgical excision 26 . Results with other lasers like PDL, 980nm diode laser, Nd:YAG lasers, and Er:YAG laserswere also good in terms of pa ent sa sfac on and recurrence. [27] [28] [29] [30] 33, 34 In these studies, combina on approach showed be er result than solo therapy. Laser treatments were mainly combined with surgical excision or ILCS. 26, 27, 30, 33 However, not all studies with laser showed exci ng results. 2 studies with CO2 laser and 1 study with PDLshowed complete recurrence of keloids. 22, 23, 45 These diff erent outcome conclusionsare likely due to varia ons in keloid size, loca on and dura on and also varia ons in treatment dosimetry and protocols.
Similarly, studies with RF showed be er result when adjunc ve ILCS was used. 38 Three studies on RF reviewed here, all of which showed good result with no recurrence except one study where a small scar recurred in 10% of cases at fi ve year follow up. 15, 37, 38 However, none of the other studies did this long dura on follow up of fi ve years. Both the studies on PDT reviewed here used MAL as a photosensi zing agent and irradiated the lesions using a red light with a wave length of 630 nm and light dosage at 37 J/ cm2. 18, 39 All the pa ents showed marked improvement and no recurrence except one pa ent with a keloid in a stress proneanatomical loca on that recurred. 39 Unfortunately, studies on UVA1 failed to give exci ng results. Three studies on UVA1 reviewed here reported the improvement in symptoms like itching and tenderness, but none reported the reduc on of scar volume. [40] [41] [42] Unfortunately, most of the studies on keloids are noncontrolledarm,non-blinded, and non-randomized. The challenge of conduc ng double-blind RCTs for keloid treatment is the inherent diffi culty in blinding pa ents and treatment operators. This may be the reason why cutaneous scar management has relied mainly on the experience of prac oners rather than on the results of large-scale randomized, controlled trials and evidence-based studies. 43 
Conclusion
In the case of keloids, combina on approach is the best treatment modality. Successful therapeu c management need to address the condi ons that ini ate keloid forma on, if not, keloid recurrence is likely and op mal management may not be achieved. In addi on, it is highly desirable that many standard prac ces and new emerging therapies undergo largescale studies with long-term follow-up before being recommended conclusively as alterna ve therapies for the treatment of keloid. Moreover, RCTs are urgently needed.
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